From: Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
Endpoints | Genotype-guided group (n = 99) | Non-genotype-guided group (n = 102) | HR(95%CI) | p-Value |
---|---|---|---|---|
The primary endpoints (a composite of stroke and myocardial infarction) | 13(13.1%) | 30(29.4%) | 0.39(0.20–0.75) | 0.004 |
The secondary end points | ||||
Recurrent stroke | 12(12.1%) | 28(27.5%) | 0.39(0.20–0.76) | 0.006 |
Ischemic stroke | 11(11.1%) | 26(25.4%) | 0.38(0.19–0.77) | 0.007 |
Hemorrhagic stroke | 1(1.0%) | 2(2.0%) | 0.44(0.04–4.88) | 0.505 |
Myocardial infarction | 1(1.0%) | 2(2.0%) | 0.45(0.04–4.92) | 0.509 |
All-cause mortality | 3(3.0%) | 8(7.8%) | 0.34(0.09–1.29) | 0.114 |